Update (July 3, 2026): Feline Aortic Thromboembolism — Acute Management and Long-Term Thromboprophylaxis (Guillaumin 2024 JFMS Review)

Bottom line.

• Feline aortic thromboembolism (FATE or CATE) carries a grave acute prognosis: roughly 30-50% of cats die or are euthanized at presentation; survivors face a high recurrence risk without thromboprophylaxis.
• A 2024 review by Guillaumin in the Journal of Feline Medicine and Surgery summarizes recent advances including thrombolysis (tissue plasminogen activator — tPA), supportive analgesia/pain management, adjunct drugs (cilostazol, flunarizine), and updated long-term thromboprophylaxis guidance.
• Aspirin is no longer recommended; clopidogrel (confirmed superior in the FAT CAT RCT) remains the backbone of secondary prevention.
• Acute management centers on analgesia (opioids or butorphanol), warming, fluid support, heparin anticoagulation, and close monitoring for reperfusion injury; thrombolysis with tPA can accelerate limb reperfusion but carries significant hemorrhagic risk.
• This is a clinician-facing evidence summary. It is not a treatment protocol; confirm analgesic dosing, heparin protocols, and tPA eligibility criteria against current formularies and emergency/critical care guidance.

Clinical facts

• Pathophysiology: FATE most commonly results from left atrial stasis (spontaneous echocardiographic contrast, reduced LA appendage velocity) associated with cardiomyopathy (HCM predominant), with thrombus lodgment at the aortic trifurcation ("saddle thrombus") causing acute ischemic neuromyopathy of the hindlimbs.
• Classic presentation: Acute-onset hindlimb paresis or paralysis, absent femoral pulses, cold cyanotic pads, extreme pain, vocalization. Forelimb or other vessel involvement is less common.
• Prognostic factors: Survival to discharge is reported in approximately 30-50% of treated cats; predictors of poor outcome include bilateral limb involvement, hypothermia, and cardiac disease severity (presence of CHF worsens prognosis significantly).
• Recurrence: Without thromboprophylaxis, median time to recurrent ATE is short; the FAT CAT trial demonstrated a median of 128 days to recurrent ATE or cardiac death with aspirin.
• Underlying disease: >90% of FATE cases have underlying cardiomyopathy; thoracic radiographs and echocardiography are essential for characterizing cardiac status and guiding management.

Managing an acute FATE case in your clinic this week?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, analgesic guidance, and discharge planning support to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

2024 JFMS review: acute treatment and emerging approaches

Guillaumin's 2024 review in JFMS provides an updated framework for acute FATE management for general practitioners.¹ Supportive care remains the cornerstone: aggressive analgesia (opioids are the standard; ensure adequate pain management in what is one of the most painful presentations in feline emergency medicine), external warming (avoid excessive heat to already ischemic tissues), judicious fluid support balancing perfusion needs against cardiac decompensation risk, and heparin anticoagulation to limit clot propagation. The review highlights that aspirin is no longer recommended in the acute or chronic setting. Adjunct drugs discussed include cilostazol (a phosphodiesterase III inhibitor with antiplatelet activity and possible vasodilatory benefit) and flunarizine (a calcium channel blocker used in some European centers for vasodilation) — both with limited evidence but discussed in the context of improving collateral flow.

Thrombolysis with tissue plasminogen activator (tPA) via the BLASTT protocol (Bilateral Lysis of Aortic Saddle Thrombus with early tPA) can accelerate limb reperfusion in candidates who survive the initial period, but carries significant hemorrhagic risk including fatal intracranial hemorrhage; eligibility criteria, dosing protocols, and intensive monitoring requirements make this an advanced intervention appropriate only in settings with appropriate expertise and client counseling.

Long-term thromboprophylaxis

Consistent with the ACVIM 2020 consensus and FAT CAT trial findings, Guillaumin's review confirms clopidogrel as the foundation of long-term secondary thromboprophylaxis post-FATE.^1,2 Combination antiplatelet strategies (adding low-dose aspirin or an oral factor Xa inhibitor to clopidogrel) may be considered in very high-risk cats, per ACVIM guidance at low level of evidence.

Prognostic counseling at presentation

A key message from current evidence is that approximately 50% of cats with acute FATE will not survive to discharge, and among those that do, recurrence without thromboprophylaxis is common. Structured prognostic conversations at initial presentation — covering the acute survival odds, the likelihood of achieving functional limb use, the underlying cardiac disease, and the long-term thromboprophylaxis commitment — are as important as the immediate medical management. Euthanasia at initial presentation is not an unreasonable or uncommon outcome and should be presented as a legitimate choice where welfare concerns dominate.

How this fits clinical practice

FATE is one of the most acutely distressing presentations in feline medicine for clinicians, owners, and patients. The 2024 Guillaumin review reinforces a framework that is largely supportive, with analgesia, anti-coagulation, and careful monitoring as the core — while offering context for when advanced interventions such as tPA thrombolysis might be considered. The long-term picture centers on clopidogrel thromboprophylaxis and ongoing cardiac management of the underlying cardiomyopathy.

Always confirm analgesic dosing, heparin protocols, and tPA eligibility criteria against current emergency medicine formularies and specialist guidance.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Guillaumin J. 2024. Feline aortic thromboembolism: recent advances and future prospects. J Feline Med Surg. https://journals.sagepub.com/doi/10.1177/1098612X241257878
2. Luis Fuentes V, Abbott J, Chetboul V, et al. 2020. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J Vet Intern Med 34(3):1062-1077. https://onlinelibrary.wiley.com/doi/10.1111/jvim.15745

Changelog

• 2026-07-03: First published.